What does rAAT stand for?

Recombinant Alpha 1-Antitrypsin

This definition appears very rarely and is found in the following Acronym Finder categories:

Science, medicine, engineering, etc.

Other Resources:

<< Previous	Abbreviation Database Surfer		Next >>
Runway Awareness and Advisory System Russian Academy of Agricultural Sciences Royal Australian Army Service Corps Reynolds Adolescent Adjustment Screening Inventory Ramona Alliance Against Sunrise Powerlink (California) Resource Allocation Analysis Service and Portal (computing literature; University of Calgary, Alberta, Canada) Reusable Ada Avionics Software Package Radiowave, Auditory, Assaultive, Transmitting (implants) Rapid Anterograde Axoplasmic Transport Rapid Anti-Robot Assault Team (Transformers)		Reduced Agent and Area Treatment (pest control) Regionale Aanpak Aansluitende Trajecten (Dutch: Connecting Regional Approach Paths; economic research program) Royal Automobile Association of Thailand Recent Advances in Asistive Technology and Engineering Recovery Attitude and Treatment Evaluator Robot Armies Are the Future (online magazine) RCRA Administrative Action Tracking System (EPA) Receivables Agency Audit and Tracking System Remote Area Aboriginal and Torres Strait Islander Child Care (Australia) Recombinant Adeno-Associated Virus

Samples in periodicals archive:

It includes production of recombinant alpha 1-antitrypsin, the protein used in the firm's lead product Respriva.

U.S. Patent Disclosures

of the clinical development for recombinant alpha 1-antitrypsin (rAAT) in dermatological applications; - Pathogen Removal and Diagnostic Technologies Inc.

ProMetic's Quarterly Business Fact Sheet is Available

The patent (United States Patent 7,247,704) covers compositions of matter and uses of Aeriva[TM], a fusion protein that combines Secretory Leukocyte Protease Inhibitor (SLPI) and recombinant alpha 1-antitrypsin (rAAT).

Arriva Pharmaceuticals Granted Fusion Protein Patent

ProMetic Life Sciences (PLI:TSX) announced today that the results of two clinical trials designed to demonstrate safety and efficacy of recombinant Alpha 1-Antitrypsin (rAAt in a topical gel formulation) will be released during the week of October 4, 2004.

ProMetic will Announce Results of Clinical Trials for Recombinant ...

for the development of recombinant alpha 1-antitrypsin (rAAT) in hereditary emphysema, asthma and other respiratory indications.

ARRIVA ARRIVES, CLOSES $28M SERIES D ROUND FOR TRIALS

ALAMEDA, California, September 1 /PRNewswire/ -- - Results to Be Presented at the European Respiratory Society Meeting Show That Treated Animals Exhibit Significantly Less Inflammation and a 73% Reduction in the Breakdown of Lung Tissue Today, Arriva Pharmaceuticals announced that it will present new data on the company's lead molecule, recombinant Alpha 1-Antitrypsin (rAAT) at the European Respiratory Society (ERS) Meeting in Glasgow next week.

Arriva Pharmaceuticals Announces Positive Data From Pre-Clinical ...

1 /PRNewswire/ -- Today, Arriva Pharmaceuticals announced that it will present new data on the company's lead molecule, recombinant Alpha 1-Antitrypsin (rAAT) at the European Respiratory Society (ERS) Meeting in Glasgow next week.

Arriva Pharmaceuticals Announces Positive Data From Pre-Clinical ...

com/ (live and archived) Subjects to be discussed: ------------------------- - Third quarter results (to be announced November 28, 7:30am) - PRDT's prion reduction product announcement (November 19, 2003) - Tunisian project (October 15, 2003) - Arriva-ProMetic phase II clinical study on recombinant Alpha 1-antitrypsin (rAAT) gel (October 9, 2003) - Strategic alliance with the NRC Biotechnology Research Institute (September 29, 2003) For access to the latest press releases, we invite you to visit our website at http://www.

ProMetic Life Sciences Inc. Will Hold a Conference Call to Discuss ...